Breaking News

AstraZeneca to Buy Respiratory Drug Company, Amirall

August 1, 2014

AZ will acquire the Catalan company, which specializes in drugs for COPD and other respiratory diseases

AstraZeneca has bought the Catalan company, Amirall's, respiratory therapies business, including rights to Eklira, a drug that is designed to treat chronic obstructive pulmonary disease (COPD) and represents 14.4% of the company's total sales. The Catalan News Agency reported this news on Wednesday, July 30, 2014.

AstraZeneca will reportedly pay $875 million initially, and up to $1.22 billion, depending on product development success, new product launches and sales.  "A significant number of employees" will reportedly be transferred to AstraZeneca, the news agency reported.   

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks